Sigma Of Australia Loses Enough Market Value To Jeopardize Aspen Buy
This article was originally published in PharmAsia News
Executive SummaryAustralia's Sigma Pharmaceuticals has lost so much of its stock-market value, a buyout offer by South Africa's Aspen Pharmacare Holdings may be in jeopardy
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.